Correction to: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis

被引：0

作者：

Hagop M. Kantarjian

Timothy P. Hughes

Richard A. Larson

Dong-Wook Kim

Surapol Issaragrisil

Philipp le Coutre

Gabriel Etienne

Carla Boquimpani

Ricardo Pasquini

Richard E. Clark

Viviane Dubruille

Ian W. Flinn

Slawomira Kyrcz-Krzemien

Ewa Medras

Maria Zanichelli

Israel Bendit

Silvia Cacciatore

Ksenia Titorenko

Paola Aimone

Giuseppe Saglio

Andreas Hochhaus

机构：

[1] The University of Texas MD Anderson Cancer Center,Department of Medicine, Section of Hematology/Oncology

[2] South Australian Health and Medical Research Institute,Seoul St. Mary’s Hospital, College of Medicine

[3] University of Adelaide,Faculty of Medicine, Siriraj Hospital

[4] University of Chicago,Hematology Department

[5] Catholic University of Korea,Clinical Hematology

[6] Mahidol University,Department of Hematology and Bone Marrow Transplantation

[7] Charité - Universitätsmedizin Berlin,Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation

[8] Institut Bergonié,Instituto de Tratamento do Câncer Infantil

[9] Hemorio,Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco

[10] Institute of Hematology,Immuno

[11] Oncoclínica Rio de Janeiro,Hematology (LIM

[12] Universidade Federal do Paraná,31), Department of Hematology

[13] Hospital de Clinicas,Division of Internal Medicine and Hematology

[14] Royal Liverpool University Hospital,undefined

[15] Nantes University Hospital,undefined

[16] Sarah Cannon Research Institute,undefined

[17] Medical University of Silesia,undefined

[18] Wroclaw Medical University,undefined

[19] Instituto da Criança,undefined

[20] Hospital das Clínicas,undefined

[21] Universidade de São Paulo,undefined

[22] Hospital das Clínicas HCFMUSP,undefined

[23] Faculdade de Medicina,undefined

[24] Universidade de São Paulo,undefined

[25] Novartis Pharma AG,undefined

[26] Novartis Pharmaceuticals Corporation,undefined

[27] University of Turin,undefined

[28] Universitätsklinikum Jena,undefined

来源：

Leukemia | 2021年 / 35卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：2142 / 2143

页数：1

共 50 条

[1] Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis
Kantarjian, Hagop M.
Hughes, Timothy P.
Larson, Richard A.
Kim, Dong-Wook
Issaragrisil, Surapol
le Coutre, Philipp
Etienne, Gabriel
Boquimpani, Carla
Pasquini, Ricardo
Clark, Richard E.
Dubruille, Viviane
Flinn, Ian W.
Kyrcz-Krzemien, Slawomira
Medras, Ewa
Zanichelli, Maria
Bendit, Israel
Cacciatore, Silvia
Titorenko, Ksenia
Aimone, Paola
Saglio, Giuseppe
Hochhaus, Andreas
LEUKEMIA, 2021, 35 (02) : 440 - 453
[2] Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis
Hagop M. Kantarjian
Timothy P. Hughes
Richard A. Larson
Dong-Wook Kim
Surapol Issaragrisil
Philipp le Coutre
Gabriel Etienne
Carla Boquimpani
Ricardo Pasquini
Richard E. Clark
Viviane Dubruille
Ian W. Flinn
Slawomira Kyrcz-Krzemien
Ewa Medras
Maria Zanichelli
Israel Bendit
Silvia Cacciatore
Ksenia Titorenko
Paola Aimone
Giuseppe Saglio
Andreas Hochhaus
Leukemia, 2021, 35 : 440 - 453
[3] Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: Enestnd 10-Year Analysis
Hughes, Timothy P.
Saglio, Giuseppe
Larson, Richard A.
Kantarjian, Hagop M.
Kim, Dong-Wook
Issaragrisil, Surapol
Le Coutre, Philipp
Etienne, Gabriel
Boquimpani, Carla
Clark, Richard E.
Dubruille, Viviane
Flinn, Ian W.
Kyrcz-Krzemien, Slawomira
Medras, Ewa
Zanichelli, Maria
Bendit, Israel
Sondhi, Manu
Titorenko, Ksenia
Nourry-Boulot, Claire
Aimone, Paola
Hochhaus, Andreas
BLOOD, 2019, 134
[4] Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis (vol 35, 20-LEU-1554R, 2021)
Kantarjian, Hagop M.
Hughes, Timothy P.
Larson, Richard A.
Kim, Dong-Wook
Issaragrisil, Surapol
le Coutre, Philipp
Etienne, Gabriel
Boquimpani, Carla
Pasquini, Ricardo
Clark, Richard E.
Dubruille, Viviane
Flinn, Ian W.
Kyrcz-Krzemien, Slawomira
Medras, Ewa
Zanichelli, Maria
Bendit, Israel
Cacciatore, Silvia
Titorenko, Ksenia
Aimone, Paola
Saglio, Giuseppe
Hochhaus, Andreas
LEUKEMIA, 2021, 35 (07) : 2142 - 2143
[5] Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
A Hochhaus
G Saglio
T P Hughes
R A Larson
D-W Kim
S Issaragrisil
P D le Coutre
G Etienne
P E Dorlhiac-Llacer
R E Clark
I W Flinn
H Nakamae
B Donohue
W Deng
D Dalal
H D Menssen
H M Kantarjian
Leukemia, 2016, 30 : 1044 - 1054
[6] Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
Hochhaus, A.
Saglio, G.
Hughes, T. P.
Larson, R. A.
Kim, D-W
Issaragrisil, S.
le Coutre, P. D.
Etienne, G.
Dorlhiac-Llacer, P. E.
Clark, R. E.
Flinn, I. W.
Nakamae, H.
Donohue, B.
Deng, W.
Dalal, D.
Menssen, H. D.
Kantarjian, H. M.
LEUKEMIA, 2016, 30 (05) : 1044 - 1054
[7] Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
Saglio, Giuseppe
Kim, Dong-Wook
Issaragrisil, Surapol
le Coutre, Philipp
Etienne, Gabriel
Lobo, Clarisse
Pasquini, Ricardo
Clark, Richard E.
Hochhaus, Andreas
Hughes, Timothy P.
Gallagher, Neil
Hoenekopp, Albert
Dong, Mei
Haque, Ariful
Larson, Richard A.
Kantarjian, Hagop M.
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (24): : 2251 - 2259
[8] Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: 10-year follow‑up of the Japanese subgroup of the randomized ENESTnd trial
Hirohisa Nakamae
Masahide Yamamoto
Emiko Sakaida
Yoshinobu Kanda
Ken Ohmine
Takaaki Ono
Itaru Matsumura
Maho Ishikawa
Makoto Aoki
Akio Maki
Hirohiko Shibayama
International Journal of Hematology, 2022, 115 : 33 - 42
[9] ENESTnd Update: Continued Superiority of Nilotinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP)
Hughes, Timothy P.
Hochhaus, Andreas
Saglio, Giuseppe
Kim, Dong-Wook
Jootar, Saengsuree
le Coutre, Philipp D.
Reiffers, Josy
Pasquini, Ricardo
Lobo, Clarisse
Clark, Richard E.
Gallagher, Neil J.
Hoenekopp, Albert
Haque, Ariful
Larson, Richard A.
Kantarjian, Hagop M.
BLOOD, 2010, 116 (21) : 94 - 95
[10] ENESTnd 5-year (y) update: Long-term outcomes of patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with frontline nilotinib (NIL) versus imatinib (IM).
Larson, Richard A.
Kim, Dong-Wook
Jootar, Saengsuree
Pasquini, Ricardo
Clark, Richard E.
Lobo, Clarisse
Goldberg, Stuart L.
Shibayama, Hirohiko
Hochhaus, Andreas
Saglio, Giuseppe
Kantarjian, Hagop M.
Kemp, Charisse
Deng, Weiping
Menssen, Hans D.
Hughes, Timothy P.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)

← 1 2 3 4 5 →